{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:53:32Z","timestamp":1790704412408,"version":"4.1.0"},"reference-count":29,"publisher":"Europa Digital & Publishing","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EuroIntervention"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.4244\/eij-d-17-00518","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T03:29:14Z","timestamp":1511148554000},"page":"1226-1233","source":"Crossref","is-referenced-by-count":9,"title":["Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures"],"prefix":"10.4244","volume":"13","author":[{"given":"Paul","family":"Guedeney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadjib","family":"Hammoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Duthoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Silvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Pousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Isnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Redheuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Kerneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2774","reference":[{"key":"key-2017111872850-0","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.110.976449","article-title":"Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.","volume":"123","author":"Reddy VY.","year":"2011","journal-title":"Circulation."},{"key":"key-2017111872850-1","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1093\/eurheartj\/ehv730","article-title":"Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry.","volume":"37","author":"Boersma LV.","year":"2016","journal-title":"Eur Heart J."},{"key":"key-2017111872850-2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jacc.2016.10.010","article-title":"Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation.","volume":"69","author":"Reddy VY.","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"key-2017111872850-3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ccd.24875","article-title":"Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies.","volume":"82","author":"Abaci A.","year":"2013","journal-title":"Catheter Cardiovasc Interv."},{"key":"key-2017111872850-4","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","article-title":"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.","volume":"368","author":"Carroll JD.","year":"2013","journal-title":"N Engl J Med."},{"key":"key-2017111872850-5","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.4244\/EIJ-D-15-00499","article-title":"AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure.","volume":"12","author":"Trabattoni D.","year":"2017","journal-title":"EuroIntervention."},{"key":"key-2017111872850-6","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.jacc.2014.09.045","article-title":"Procedural results and safety of common interventional procedures in congenital heart disease: initial report from the National Cardiovascular Data Registry.","volume":"64","author":"Moore JW.","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"key-2017111872850-7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCINTERVENTIONS.113.001254","article-title":"Transcatheter closure of large atrial septal defects: feasibility and safety in a large adult and pediatric population.","volume":"7","author":"Baruteau AE.","year":"2014","journal-title":"Circ Cardiovasc Interv."},{"key":"key-2017111872850-8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jacc.2003.10.030","article-title":"Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients.","volume":"43","author":"Krumsdorf U.","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"key-2017111872850-9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.CIR.95.1.118","article-title":"Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.","volume":"95","author":"Cosmi B.","year":"1997","journal-title":"Circulation."},{"key":"key-2017111872850-10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/eurheartj\/ehn008","article-title":"Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.","volume":"29","author":"Montalescot G.","year":"2008","journal-title":"Eur Heart J."},{"key":"key-2017111872850-11","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(02)02531-7","article-title":"A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention.","volume":"40","author":"Choussat R.","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"key-2017111872850-12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2125.2005.02452.x","article-title":"Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.","volume":"60","author":"Sanchez-Pena P.","year":"2005","journal-title":"Br J Clin Pharmacol."},{"key":"key-2017111872850-13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.","volume":"355","author":"Montalescot G.","year":"2006","journal-title":"N Engl J Med."},{"key":"key-2017111872850-14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.CIR.0000136830.65073.C7","article-title":"Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.","volume":"110","author":"Montalescot G.","year":"2004","journal-title":"Circulation."},{"key":"key-2017111872850-15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.","volume":"378","author":"Montalescot G.","year":"2011","journal-title":"Lancet."},{"key":"key-2017111872850-16","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1136\/bmj.e553","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.","volume":"344","author":"Silvain J.","year":"2012","journal-title":"BMJ."},{"key":"key-2017111872850-17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.amjcard.2013.07.003","article-title":"A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).","volume":"112","author":"Collet JP.","year":"2013","journal-title":"Am J Cardiol."},{"key":"key-2017111872850-18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow\u2019s triad revisited.","volume":"373","author":"Watson T.","year":"2009","journal-title":"Lancet."},{"key":"key-2017111872850-19","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.","volume":"123","author":"Mehran R.","year":"2011","journal-title":"Circulation."},{"key":"key-2017111872850-20","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"Garcia DA.","year":"2012","journal-title":"Chest."},{"key":"key-2017111872850-21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.","volume":"349","author":"Lee AY.","year":"2003","journal-title":"N Engl J Med."},{"key":"key-2017111872850-22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199709043371002","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l\u2019Embolie Pulmonaire.","volume":"337","author":"Simonneau G.","year":"1997","journal-title":"N Engl J Med."},{"key":"key-2017111872850-23","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.","volume":"354","author":"Antman EM.","year":"2006","journal-title":"N Engl J Med."},{"key":"key-2017111872850-24","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jacc.2007.01.093","article-title":"Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.","volume":"49","author":"Gibson CM.","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"key-2017111872850-25","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014 ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).","volume":"35","author":"Windecker S.","year":"2014","journal-title":"Eur Heart J."},{"key":"key-2017111872850-26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).","volume":"37","author":"Roffi M.","year":"2016","journal-title":"Eur Heart J."},{"key":"key-2017111872850-27","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/01.CIR.101.10.1083","article-title":"Low molecular weight heparin after mechanical heart valve replacement.","volume":"101","author":"Montalescot G.","year":"2000","journal-title":"Circulation."},{"key":"key-2017111872850-28","first-page":"309","article-title":"Interatrial septal defect closure for cerebrovascular accidents: exploring the role of various anticoagulants.","volume":"19","author":"Shammas NW.","year":"2007","journal-title":"J Invasive Cardiol."}],"container-title":["EuroIntervention"],"original-title":[],"deposited":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T03:29:43Z","timestamp":1511148583000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.pcronline.com\/eurointervention\/125th_issue\/191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["EIJ-D-17-00518"],"URL":"https:\/\/doi.org\/10.4244\/eij-d-17-00518","relation":{},"ISSN":["1774-024X"],"issn-type":[{"value":"1774-024X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}